159 related articles for article (PubMed ID: 36905959)
1. Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: A nationwide US study.
Schoder K; Zhu Y; Schneeweiss S; Merola JF; Savage TJ; Gibbs LR; Schneeweiss MC
J Am Acad Dermatol; 2023 Jul; 89(1):178-181. PubMed ID: 36905959
[No Abstract] [Full Text] [Related]
2. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review.
Akuffo-Addo E; Nicholas MN; Lansang P
J Cutan Med Surg; 2023; 27(2):177-178. PubMed ID: 36721993
[No Abstract] [Full Text] [Related]
3. Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: A US nationwide cohort study.
Schneeweiss MC; Wyss R; Schneeweiss S; Anand P; Jin Y; Dicesare E; Glynn RJ; Merola JF
J Am Acad Dermatol; 2024 Jan; 90(1):134-137. PubMed ID: 37604229
[No Abstract] [Full Text] [Related]
4. Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis.
Anand P; Schneeweiss S; Mostaghimi A; Schneeweiss MC
Pediatr Dermatol; 2023 Jan; 40(1):132-134. PubMed ID: 36403606
[TBL] [Abstract][Full Text] [Related]
5. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
Bakker DS; Ariens LFM; Giovannone B; Hijnen D; Delemarre EM; Knol E; Nierkens S; de Bruin-Weller MS; Thijs JL; Drylewicz J
Allergy; 2020 Dec; 75(12):3287-3289. PubMed ID: 33305359
[No Abstract] [Full Text] [Related]
6. Successful dose reduction of dupilumab in atopic dermatitis.
Ardern-Jones MR; Buchanan EE; Njungu S; O'Driscoll D
Br J Dermatol; 2023 Apr; 188(5):678-679. PubMed ID: 36662536
[No Abstract] [Full Text] [Related]
7. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?
Mastorino L; Gelato F; Richiardi I; Cavaliere G; Quaglino P; Ortoncelli M; Ribero S
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e691-e692. PubMed ID: 36688263
[No Abstract] [Full Text] [Related]
8. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients.
Escolà H; Figueras-Nart I; Bonfill-Orti M; Coll Puigserver N; Martin-Santiago A; Rodríguez Serna M; Sánchez Hernández MC; Sanz-Cabanillas JL; Taberner R; Zaragoza-Ninet V; Pujol RM; Curto-Barredo L
J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):e1156-e1160. PubMed ID: 37143399
[No Abstract] [Full Text] [Related]
9. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
Guédon C; Tauber M; Linder C; Paul C; Shourick J
Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
[No Abstract] [Full Text] [Related]
10. Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis.
Anand P; Schneeweiss S; Mostaghimi A; Schneeweiss MC
Pharmacoepidemiol Drug Saf; 2023 May; 32(5):567-576. PubMed ID: 36527432
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease.
Alegre-Bailo A; Sánchez-Gilo A; Gonzalo González I; Vicente Martín FJ
Australas J Dermatol; 2024 Feb; 65(1):63-66. PubMed ID: 37929636
[TBL] [Abstract][Full Text] [Related]
12. Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study.
Kang DH; Kwon SH; Lew BL
J Dermatol; 2024 Mar; 51(3):e63-e65. PubMed ID: 37950501
[No Abstract] [Full Text] [Related]
13. Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
Tierney E; Evans P; Broderick V; Wynn R; Irvine AD
Br J Dermatol; 2024 Mar; 190(4):581-583. PubMed ID: 38123149
[No Abstract] [Full Text] [Related]
14. Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab.
Wang M; Zheng Q; Tang S; Shen F; Jiang W
Acta Derm Venereol; 2022 Jun; 102():adv00744. PubMed ID: 35670327
[No Abstract] [Full Text] [Related]
15. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.
Sánchez-García V; Navarro-Triviño FJ; Silvestre JF
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1426-e1429. PubMed ID: 37458506
[No Abstract] [Full Text] [Related]
16. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study.
Pezzolo E; Rossi M; Caroppo F; Bianchelli T; Belloni Fortina A; Giacchetti A; Calzavara Pinton P; Naldi L
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e757-e759. PubMed ID: 36662631
[No Abstract] [Full Text] [Related]
17. Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab.
Dekkers C; der Wal MMV; El Amrani M; Luin MV; Bakker DS; Bruin-Weller M; van Wijk F
J Invest Dermatol; 2023 Sep; 143(9):1822-1825.e3. PubMed ID: 36997108
[No Abstract] [Full Text] [Related]
18. No association between dupilumab use and short-term cancer development in atopic dermatitis patients.
Owji S; Ungar B; Dubin DP; Poplausky D; Young JN; Ghalili S; Han J; Srinivasan D; Packer S; Pavel AB; Correa da Rosa J; Guttman-Yassky E; Gulati N
J Allergy Clin Immunol Pract; 2023 May; 11(5):1548-1551. PubMed ID: 36581076
[No Abstract] [Full Text] [Related]
19. Severe atopic dermatitis treated successfully with dupilumab throughout pregnancy.
Costley M; Murphy B
Clin Exp Dermatol; 2022 May; 47(5):960-961. PubMed ID: 34856015
[No Abstract] [Full Text] [Related]
20. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
Br J Dermatol; 2023 Jul; 189(2):e39. PubMed ID: 37459131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
